Evaluating cardiac risk: exposure response analysis in early clinical drug development

نویسندگان
چکیده

برای دانلود باید عضویت طلایی داشته باشید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Establishing Good Practices for Exposure–Response Analysis of Clinical Endpoints in Drug Development

This tutorial aims at promoting good practices for exposure-response (E-R) analyses of clinical endpoints in drug development. The focus is on practical aspects of E-R analyses to assist modeling scientists with a process of performing such analyses in a consistent manner across individuals and projects and tailored to typical clinical drug development decisions. This includes general considera...

متن کامل

Early clinical exposure program in learning renal physiology

Introduction: Teaching renal physiology for undergraduatemedical students in an understandable way using methods whichimprove their deep learning has always been a problem. In thisstudy, Early Clinical Exposure (ECE) was used in teaching renalphysiology for the second year medical students in Shiraz MedicalSchool. This article aims to introduce and develop this programand also measure the attit...

متن کامل

What Are the Objectives of Early Clinical Exposure?

Introduction: In recent decades, medical education has been following new approaches to early clinical exposure. This study was designed to determine early clinical exposure (ECE) objectives and their availability and importance from the participants’ viewpoint. Methods: In a descriptive study, 70 students who had participated in ECE at Isfahan Medical University were asked to complete a quest...

متن کامل

Cardiac safety, risk management, and oncology drug development.

Cardiac safety biomarkers are increasingly employed in the preclinical and clinical development of investigational oncology products. Irrespective of overt clinical toxicities, cardiacrelated laboratory tests can influence decision making at many levels during the conduct of clinical studies, including eligibility for protocol therapy, dose delivery or discontinuation, and analyses of optimal d...

متن کامل

[Evaluating cardiac risk in noncardiac surgery].

In the United States, more than 33 million patients undergo noncardiac surgery each year, at a cost of 450 000 million dollars per year. Approximately 4% of these patients present perioperative complications, at an additional cost of 25 000 million dollars per year.1 The number of cardiovascular complications arising from non-cardiac surgery exceeds 1 million patients worldwide.2 Due to the inc...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

ژورنال

عنوان ژورنال: Drug, Healthcare and Patient Safety

سال: 2018

ISSN: 1179-1365

DOI: 10.2147/dhps.s133286